Anti-Inflammatories: Small Molecule Approaches

Venue: San Diego

Location: San Diego, California, United States

Event Date/Time: Apr 17, 2012 End Date/Time: Apr 18, 2012
Report as Spam


JAK kinase inhibitors will probably be the first new class of oral anti-inflammatories on the market, with the first one likely to receive approval end of 2012. But which JAK or combinations of JAK enzymes is going to prove the best to inhibit in terms of side effects and overall risk benefit profile to patients? How are the other kinase inhibitors aimed at targeting SYK and BTK, targeted for autoimmune disease but with broader potential in diseases such as cancer, progressing?